Total
0
Shares
Volpara Health Technologies (ASX:VHT) - CEO, Ralph Highnam
CEO, Ralph Highnam
Source: Callaghan Innovation
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Volpara Health Technologies (VHT) pens a collaboration agreement with Invitae Corporation to bring its genetic testing services to Volpara’s customers in the United States
  • VHT will integrate Invitae into its software workflow to offer women further access to comprehensive genetic testing services in different clinical settings
  • The company says the agreement will ensure the right patients get seamless access to genetic testing at the right time
  • Volpara Health Technologies is up 1.75 per cent, trading at $1.16 at 4:20 pm AEST

Volpara Health Technologies (VHT) has penned a collaboration agreement with Invitae Corporation to bring its genetic testing services to Volpara’s customers in the United States.

VHT says it will integrate Invitae into its software workflow to offer women further access to comprehensive genetic testing services in different clinical settings. As part of the collaboration agreement with Invitae, Volpara says it could offer increased value to mutual customers upon successful clinical implementation.

Volpara is a health technology company that offers screening clinics, providing feedback on breast density, compression, dose, and quality, while its practice management software helps with reimbursement and patient tracking.

Along with supplemental screening, such as ultrasound and MRI, genetic testing assists in earlier cancer detection and is critical in reducing treatment costs and increasing the chances of survival.

The company says at least one Volpara software product is used with over 32 per cent of women who attend a breast cancer screening each year in the United States.  

 “Volpara continues to be proud of its major role in driving the adoption of personalised breast screening in the United States,” Dr. Ralph Highnam, Group CEO of Volpara, said.

“Our relationship with Invitae adds a prominent partner to our breast health platform and will allow us to offer increased value to our customers by ensuring that the right patients get seamless access to the right genetic testing at the right time.”

Volpara Health Technologies was up 1.75 per cent, trading at $1.16 at 4:20 pm AEST.

VHT by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.